KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Gross Margin (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Gross Margin data on record, last reported at 79.53% in Q4 2025.

  • For Q4 2025, Gross Margin rose 83.0% year-over-year to 79.53%; the TTM value through Dec 2025 reached 79.39%, up 370.0%, while the annual FY2025 figure was 79.39%, 370.0% up from the prior year.
  • Gross Margin reached 79.53% in Q4 2025 per PCRX's latest filing, down from 80.91% in the prior quarter.
  • Across five years, Gross Margin topped out at 80.91% in Q3 2025 and bottomed at 63.42% in Q4 2022.
  • Average Gross Margin over 5 years is 74.34%, with a median of 74.57% recorded in 2021.
  • Peak YoY movement for Gross Margin: crashed -1207bps in 2022, then skyrocketed 1026bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 75.5% in 2021, then fell by -16bps to 63.42% in 2022, then increased by 16bps to 73.69% in 2023, then rose by 7bps to 78.7% in 2024, then grew by 1bps to 79.53% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 79.53% in Q4 2025, 80.91% in Q3 2025, and 77.43% in Q2 2025.